Literature DB >> 24486363

Development of a multivalent, PrP(Sc)-specific prion vaccine through rational optimization of three disease-specific epitopes.

Kristen Marciniuk1, Pekka Määttänen2, Ryan Taschuk3, T Dean Airey4, Andrew Potter2, Neil R Cashman4, Philip Griebel3, Scott Napper5.   

Abstract

Prion diseases represent a novel form of infectivity caused by the propagated misfolding of a self-protein (PrP(C)) into a pathological, infectious conformation (PrP(Sc)). Efforts to develop a prion vaccine have been complicated by challenges and potential dangers associated with induction of strong immune responses to a self protein. There is considerable value in the development of vaccines that are specifically targeted to the misfolded conformation. Conformation specific immunotherapy depends on identification and optimization of disease-specific epitopes (DSEs)(1) that are uniquely exposed upon misfolding. Previously, we reported development of a PrP(Sc)-specific vaccine through empirical expansions of a YYR DSE. Here we describe optimization of two additional prion DSEs, YML of β-sheet 1 and a rigid loop (RL) linking β-sheet 2 to α-helix 2, through in silico predictions of B cell epitopes and further translation of these epitopes into PrP(Sc)-specific vaccines. The optimized YML and RL vaccines retain their properties of immunogenicity, specificity and safety when delivered individually or in a multivalent format. This investigation supports the utility of combining DSE prediction models with algorithms to infer logical peptide expansions to optimize immunogenicity. Incorporation of optimized DSEs into established vaccine formulation and delivery strategies enables rapid development of peptide-based vaccines for protein misfolding diseases.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease-Specific Epitopes; Prion diseases; Protein Misfolding; Self-Epitope; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24486363     DOI: 10.1016/j.vaccine.2014.01.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Authors:  Ryan Taschuk; Jacques Van der Merwe; Kristen Marciniuk; Andrew Potter; Neil Cashman; Philip Griebel; Scott Napper
Journal:  Prion       Date:  2015       Impact factor: 3.931

2.  EpIC: a rational pipeline for epitope immunogenicity characterization.

Authors:  Kristen Marciniuk; Brett Trost; Scott Napper
Journal:  Bioinformatics       Date:  2015-03-06       Impact factor: 6.937

Review 3.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

Review 4.  Prion diseases: immunotargets and therapy.

Authors:  Jennifer T Burchell; Peter K Panegyres
Journal:  Immunotargets Ther       Date:  2016-06-16

5.  Induction of PrPSc-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease.

Authors:  Ryan Taschuk; Erin Scruten; Murray Woodbury; Neil Cashman; Andrew Potter; Philip Griebel; Suresh K Tikoo; Scott Napper
Journal:  Prion       Date:  2017-09-03       Impact factor: 3.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.